Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is an aggressive malignancy associated with profound host immunosuppression mediated in part by FoxP3 expressing regulatory CD4+ T lymphocytes (Tregs) that down-regulate anti-tumor immunity. In order to assess whether FoxP3 was an independent driver differentially expressed in primary versus recurrent GBMs, we stained resected primary and recurrent GBM tumors for CD3, CD4, CD8 and FoxP3 expression using standard immunohistochemistry. Slides were scanned with a high-resolution scanner (ScanScope CS; Aperio), and image analysis software (Aperio ScanScope) was used to enumerate lymphocyte subpopulations allowing for high-throughput analysis and bypassing manual selection bias. As shown in previous studies, enumeration of individual lymphocyte populations did not correlate with clinical outcomes in patients with GBM. However, the CD4+ to regulatory FoxP3+ T cell ratio was diminished in recurrent disease, and increased CD3 and CD8+ to regulatory T cell ratios showed a positive correlation with survival outcomes in primary GBM. These results suggest that while absolute numbers of tumor infiltrating lymphocytes may not be informative for predicting clinical outcomes in patients with GBM, the effective balance of CD3, CD4 and CD8+ T cells to immunosuppressive FoxP3+ regulatory cells may influence clinical outcomes in this patient population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased presence of Tregs is linked to decreased patient survival in several types of malignancies [5–7].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745 · cited 1×
“CD4+FoxP3+ Tregs are essential for the active suppression of autoimmunity and inhibition of anti-tumor immune responses [10, 26].”
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Bennett, C. L., Christie, J., Ramsdell, F., Brunkow, M. E., Ferguson, P. J., Whitesell, L., Kelly, T. E., Saulsbury, F. T., Chance, P. F., & Ochs, H. D. (2001) · Nature Genetics · doi:10.1038/83713 · Cited by 3,402
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,856
Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S.-A., Wilkinson, J. E., Galas, D., Ziegler, S. F., & Ramsdell, F. (2001) · Nature Genetics · doi:10.1038/83784 · Cited by 2,636
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
Clark, W. H., Elder, D. E., Guerry, D., Braitman, L. E., Trock, B. J., Schultz, D., Synnestvedt, M., & Halpern, A. C. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.24.1893 · Cited by 1,247
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25– T cells
R.Walker, M., Kasprowicz, D. J., Gersuk, V. H., Bènard, A., Van Landeghen, M., Buckner, J. H., & Ziegler, S. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci19441 · Cited by 1,245
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Self-citationGlioma cancer stem cells induce immunosuppressive macrophages/microglia
Wu, A., Wei, J., Kong, L.-Y., Wang, Y., Priebe, W., Qiao, W., Sawaya, R., & Heimberger, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq082 · Cited by 691
deLeeuw, R. J., Kost, S. E., Kakal, J. A., & Nelson, B. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3216 · Cited by 437
Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., Garcia, J., Vogelbaum, M. A., & Finke, J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor042 · Cited by 359
Fecci, P. E., Ochiai, H., Mitchell, D. A., Grossi, P. M., Sweeney, A. E., Archer, G. E., Cummings, T., Allison, J. P., Bigner, D. D., & Sampson, J. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2070 · Cited by 347
Self-citationLohr, J., Ratliff, T., Huppertz, A., Ge, Y., Dictus, C., Ahmadi, R., Grau, S., Hiraoka, N., Eckstein, V., Ecker, R. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2557 · Cited by 337
Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas
Heimberger, A. B., Abou-Ghazal, M., Reina-Ortiz, C., Yang, D. S., Sun, W., Qiao, W., Hiraoka, N., & Fuller, G. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0320 · Cited by 332
Yuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 332
Tumor-infiltrating T lymphocytes: Friends or foes?
Yu, P., & Fu, Y.-X. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700389 · Cited by 299
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Oble, D. A., Loewe, R. P., Yu, P., & Mihm, M. C. (2009) · PubMed · Cited by 237
Immunologic Basis of Vaccine Vectors
Liu, M. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.004 · Cited by 237
Prognostic significance and mechanism of Treg infiltration in human brain tumors
Jacobs, J. F. M., Idema, A. J., Bol, K. F., Grotenhuis, J. A., de Vries, I. J. M., Wesseling, P., & Adema, G. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.05.020 · Cited by 211
Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y., Licchetta, A., Mannucci, S., Loiacono, L., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32f01 · Cited by 210
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
Goding, S. R., Wilson, K. A., Xie, Y., Harris, K. M., Baxi, A., Akpinarli, A., Fulton, A., Tamada, K., Strome, S. E., & Antony, P. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300271 · Cited by 206
Loebbermann, J., Thornton, H., Durant, L., Sparwasser, T., Webster, K. E., Sprent, J., Culley, F. J., Johansson, C., & Openshaw, P. J. (2012) · Mucosal Immunology · doi:10.1038/mi.2011.62 · Cited by 185
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival
Yang, I., Tihan, T., Han, S. J., Wrensch, M. R., Wiencke, J., Sughrue, M. E., & Parsa, A. T. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2010.03.031 · Cited by 181
Fecci, P. E., Sweeney, A. E., Grossi, P. M., Nair, S. K., Learn, C. A., Mitchell, D. A., Cui, X., Cummings, T. J., Bigner, D. D., Gilboa, E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0053 · Cited by 172
Self-citationAndaloussi, A. E., Han, Y., & Lesniak, M. S. (2006) · Journal of neurosurgery · doi:10.3171/jns.2006.105.3.430 · Cited by 157
Mitchell, D. A., Cui, X., Schmittling, R. J., Sanchez-Perez, L. A., Snyder, D. J., Congdon, K. L., Archer, G. E., Desjardins, A., Friedman, A. H., Friedman, H. S., et al. (2011) · Blood · doi:10.1182/blood-2011-02-334565 · Cited by 114
Self-citationPölcher, M., Braun, M., Friedrichs, N., Rudlowski, C., Bercht, E., Fimmers, R., Sauerwald, A., Keyver-Paik, M.-D., Kübler, K., Büttner, R., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0817-1 · Cited by 90
Phenotypic and functional characteristic of a newly identified CD8+Foxp3−CD103+ regulatory T cells
Liu, Y., Lan, Q., Lu, L., Chen, M., Xia, Z., Ma, J., Wang, J., Fan, H., Shen, Y., Ryffel, B., et al. (2013) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt026 · Cited by 84
The role of regulatory T cells in malignant glioma.
Sonabend, A. M., Rolle, C. E., & Lesniak, M. S. (2008) · PubMed · Cited by 82
The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma
Yue, Q., Zhang, X., Ye, H.-X., Wang, Y., Du, Z., Yao, Y., & Mao, Y. Q. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1314-0 · Cited by 74
Learn, C. A., Fecci, P. E., Schmittling, R. J., Xie, W., Karikari, I. O., Mitchell, D. A., Archer, G. E., Wei, Z., Dressman, H. K., & Sampson, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1727 · Cited by 71
Self-citationBiovaxID™: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma
Lee, S., Jiang, Y.-F., Park, K. U., Woo, A. F., & Neelapu, S. S. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.113 · Cited by 25
Virtual microscopy, data management and image analysis in Aperio ScanScope system.
Staniszewski, W. (2010) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-009-0115-y · Cited by 25
Virtual slides: application in pulmonary pathology consultations.
Słodkowska, J., Chyczewski, L., & Wojciechowski, M. (2008) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-008-0018-3 · Cited by 23
Xi, F., Li, B., Ye, H., & Long, D. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0127-0 · Cited by 23
Clinical significance of FOXP3 expression in human gliomas
Wang, L., Zhang, B., Xu, X., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1037-x · Cited by 17
Cited by
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Saha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 591
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
Metadata
- Authors
- Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A.
- Affiliations
- University of Florida (US)
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Mitchell, Duane A.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2015-01-03
- Volume
- 64
- Issue
- 4
- Pages
- 419-427
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC4774199
- OpenAlex
- W2066684749
- Cited by
- 196
- References
- 42
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 14 · 2023: 15 · 2022: 15 · 2021: 28 · 2020: 21 · 2019: 17 · 2018: 20 · 2017: 18 · 2016: 16 · 2015: 8
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001427, 5r01ca134844-04)
- National Cancer Institute (5R01-CA134844, R01-CA235612, R01-CA134844, P50CA108786)
- National Institute of Neurological Disorders and Stroke (R01NS067037, 5R01-NS067037)
- National Center for Research Resources (UL1RR024128)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- glioblastoma, Foxp3+ regulatory T cells, tumor-infiltrating lymphocytes, tumor recurrence, survival, CD4+ T cells, CD8+ T cells, CD3+ T cells, tumor immunosuppression, antitumor immunity, prognostic factors
- MeSH terms
- Adult, Aged, Brain Neoplasms, Female, Follow-Up Studies, Glioblastoma, Humans, Immunoenzyme Techniques, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Biomarkers, Tumor, CD4-Positive T-Lymphocytes, Survival Rate, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.